Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The thing that concerns me the most at this point is the market makers on the ask. Those guys were not there before. I think someone with a fairly large position has been dumping, which obviously is not good, but the market makers now on the ask make me wonder if the company is not diluting to raise some capital.
How long can one man's money last, especially when the company is public and you can sell some stock for some capital.
TCHAUNCY-with your background maybe you can tell me if those market makers are generally known for dilution. I have just enough in here to make me concerned. I almost never invest in a company down here in the jungle but thought it might be worth the gamble with people in charge here. Of course I am down like the rest of you guys.
This must be it.
I noticed that also but I have to agree with lifegear on this one. Too much potential to ignore.
VODG .08
O/S 12.45 million
Float 4.33 million
Take a look at a 3 yr weekly chart.
As you can see there the PPS seems to show virtually no dilution. After looking at the last few 10KSB there has been very little dilution.
Here is their latest PR.
AURORA, CO--(MARKET WIRE)--Jun 26, 2007 -- Vitro Diagnostics, Inc. (OTC BB:VODG.OB - News), dba Vitro Biopharma, announced the development of a new method to derive human pancreatic beta islets from adult pancreatic stem cells. Through research and development of stem cell differentiation methods, Vitro discovered a process that yields islets that appear structurally equivalent to those derived from the pancreas gland. These islets are produced in high yield and exhibit properties comparable to native islets including expression and secretion of biomarkers for insulin.
Dr. Jim Musick, Vitro's President and CEO, said, "The present advances in stem cell differentiation position the Company for additional commercial opportunities. We believe there is an unmet need for human beta islets in research and drug discovery applications. Our current efforts are directed towards further characterization of stem cell-derived beta islets produced by our newly discovered method and scale-up of production capacity to support anticipated initial commercial distribution."
There may also be therapeutic applications of stem cell technology in the treatment of diabetes. It has recently been shown that autologous bone marrow stem cell transplantation can slow the progression of early onset Type I diabetes probably by reducing autoimmune destruction of beta cells. A longer-term goal of the Company is to further develop its stem cell-derived beta islets for use in cell therapy of diabetes. The present advances may open opportunities to complete pre-clinical research studies and proceed with regulatory approval through the FDA, given the availability of adequate resources.
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTC BB:VODG.OB - News) http://www.vitrodiag.com, owns 29 patent-pending adult pancreatic stem cell lines that are distinct from the limited number of embryonic stem cell lines that are presently approved for federally funded research. These cell lines may have commercial application in diabetes research and therapy. The Company's reliance on adult stem cell lines obviates some ethical objections to embryonic stem cell research. Knowledge gained from its adult stem cell lines may also benefit studies of the differentiation of pleurapotent stem cell lines into human beta islets. The Company developed and manufactures the VITROCELL(TM) brand of human cell lines consisting of pituitary and pancreatic-derived cell lines and related products for various research and commercial applications.
Safe Harbor Statement
Certain statements contained herein and subsequent oral statements made by and on behalf of the Company may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are often identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's Annual Report on Form 10-KSB for the fiscal year ended October 31, 2006 and other reports filed with the Securities and Exchange Commission under the caption, "Risk Factors." Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
Contact:
CONTACT:
Dr. James Musick
Chief Executive Officer
Vitro Diagnostics, Inc.
(720) 859-4120
E-mail: Email Contact
--------------------------------------------------------------------------------
Source: Vitro Diagnostics, Inc.
IPEI moving quickly.
JMIH-PREM14C today.
http://www.sec.gov/Archives/edgar/data/1063154/000107704807000360/jmih-pre14c_7307.htm
Common Stock Capitalization Prior to Amendment:
Authorized for Issuance:
50,000,000
Outstanding:
18,863,861
Authorized and Unissued:
31,136,139
Common Stock Capitalization Following Reverse Split
and Reverse Merger (including cancellation of options held by
Jupiter Marine affiliates)
Authorized for Issuance:
50,000,000
Outstanding Post Reverse Merger:
8,139,669
Authorized and Reserved for Issuance
(Shares Underlying Preferred Stock):
10,250,000
Authorized and Unreserved for Issuance:
31,610,331
8-K 7/5/2007
Item 1.01 Entry Into a Material Definitive Agreement
Sale of Assets
On July 2, 2007, Avanir Pharmaceuticals (the “Company”) and Alamo Pharmaceuticals, LLC, a wholly owned subsidiary of the Company, (“Alamo”) entered into an asset purchase agreement (the “Agreement”) with Azur Pharma Inc. (“Azur Inc.”) and Azur Pharma International III Limited (“Azur Limited” and, together with Azur Inc., “Azur”). Pursuant to the Agreement, the Company will sell its rights to the FazaClo product (clozapine, USP) and the Company’s related assets (the “FazaClo Assets”) to Azur. The Company will receive initial consideration at closing of approximately $42,000,000 (subject to a working capital adjustment) and will have the right to receive additional payments of $4,000,000 and $6,000,000 on May 1, 2009 and December 31, 2009, respectively, if certain market conditions are met. Additionally, the Company will have the right to receive up to $2,000,000 in total royalty payments, payable at a rate of 3% of Azur’s annualized net sales of FazaClo in excess of $17,000,000. The payment obligations have been guaranteed by Azur Limited.
Upon closing, Azur will assume the Company’s contingent earn-out obligations payable to the former owners of Alamo, provided, however, that the Company will retain the obligation to issue an additional $2,000,000 promissory note payable with respect to the achievement of certain minimum FazaClo sales levels. Azur will also assume substantially all liabilities relating to the FazaClo Assets, provided that the Company will retain certain liabilities relating to potential product liability matters for products sold by the Company prior to the closing.
Azur will acquire the Company’s commercial sales force and regulatory support operations, including the FazaClo patient registry, representing approximately 85 employees (the “FazaClo Employees”). Upon the termination of the FazaClo Employees, the Company will provide accelerated vesting of outstanding stock options and other equity awards as well as the unvested portion(s), if any, of the affected employees’ 401(k) savings plans.
The Agreement contains customary representations, warranties and closing conditions. The transactions contemplated under the Agreement are expected to close by early August 2007 and the Company has agreed to provide certain support services to Azur for a transition period following closing.
Concurrently with executing the Agreement, the Company also entered into an agreement, dated July 2, 2007, with Neal R. Cutler (the “Cutler Agreement”), the holder of certain promissory notes issued by the Company in connection with the Company’s acquisition of Alamo in May 2006 (the “Notes”). Under the Cutler Agreement, the Company agreed to prepay $11,000,000 of the outstanding principal and interest owed under the Notes concurrently with the completion of the sale of the FazaClo Assets. Upon making this payment to Dr. Cutler, the Company will not be required to make any further payments on the Notes in connection with equity financings until the aggregate proceeds of future equity financings received by the Company exceeds $55,000,000, after which time the Company’s payment obligations under the Notes will resume.
Sublease of San Diego Facilities
On July 2, 2007, the Company entered into sublease agreements (the “Subleases”) with Halozyme, Inc. (“Halozyme”) for the Company’s excess leased facilities in San Diego, California. Halozyme will sublease approximately 48,758 square feet of office and laboratory space (the “Subleased Premises”) located at 11404 and 11388 Sorrento Valley Road, San Diego, California, respectively. The Company is presently the tenant at such premises under Standard Industrial Net Leases, dated February 1, 2001 and May 20, 2002 (collectively, the “Master Leases”). The Subleases will not become effective unless and until the master landlords consent thereto. Upon their effectiveness, the Subleases continue through the term of the Master Leases.
Halozyme will pay base rent for the Subleased Premises, net of costs and property taxes associated with the operation and maintenance of the Subleased Premises, starting January 1, 2008 in the amounts set forth below. Halozyme will also pay a 69.75% pro rata share of operating costs, insurance costs, costs of utilities and real property taxes for the Subleased Premises incurred by the Company under the Master Leases.
MRXT .20
Yes now over 460K in volume on the ask at .015
VODG Shares Outstanding: 12.45M Float: 4.33M Market cap just barely over 1 million. No dilution in years from what I can see or very little. Looks good here.
KING gettin a little volume on the ask this morn.
VODG-After looking at the chart,OS, and float: it is pretty apparent there is virtually no dilution taking place here in the last few years from what I can see.
VODG-level II .09 X .10-just UTed to .10 X .15. Level II is thin next MM on ask is .20. A little volume coming in.
VODG level II very thin. .09 X .10 2 X 1
Next on ask is .20
First post on GSCR on Friday goes to Power Forward.
Nice call.
If anyone has microcaptrade and saw the DEFM14C filed under ANDR I can tell you it has to be in error. The company name is moscow cablecom corp and from the best I can see the former company name of moscow was anderson group inc which probably used the ticker ANDR in the past. That is my best guess.
SEC.GOV does not show any filings for ANDR and the correct ticker symbol for moscow cablecom corp is MOCC.
Hope this helps someone.
It makes you wonder how high it could go with some real volume.
Anyone have a good contact number for Norris?
Not 15/12g but worth posting to watch-PMQC, PMQCU, PMQCW filed PREM14a after hours.
WLDA filed form defm14a today.
Looks like 12.50/share according to last PR. PPS now 11.99.
4ish percent gain.
KING .02-Bouncing here but I do not like the spread the MM's got on it. They should tighten it up here and they probably will shortly.
KING .02-Bouncing here but I do not like the spread the MM's got on it. They should tighten it up here and they probably will shortly.
KING- nice dip .0175 X .018 1 X 1 not sure if its done yet.
KING- nice dip .0175 X .018 1 X 1 not sure if its done yet.
They just dropped the bid and ask on nothing. LOL
ENCY-I got me some.
SRGG also had a 8-k out today, I briefly looked and it appeared to be a merger of some sort.
What makes you think it will be PR'd after hours?
When did this occur?
KING .019 X .02 2 X 2
Well above average volume.
KING now 2 on bid at .019
.019 X .02 2 X 1
KING-Bid building .019 X .02 2 X 1
It's been over an hour since I have seen GO TO DA MOON or see ya at 20 bucks.LOL
You guys are slacking.
KING-Nite just raised ask to .025
.019 X .02 1 X 1
REPOST-
Posted by: THE LURKER
In reply to: None Date:6/4/2007 2:06:02 AM
Post #of 3011
Hi Everyone. I was able to talk to Foster after trying to get ahold of him for a week. He said that they were going to have a PR this past week but decided to hold off to include a new development. I asked him if the PR would be this week and he said he didn't think they could get everything done by then. He did sound very optimistic about whatever is developing but wasn't giving out details that we could sink our teeth into. I know many of you are getting tired waiting for news ( I'm one of them). We all know this company could be worth a lot more than the $4-6 million market cap it has if they could just get the ball rolling. I'm hopeful the financing/JV announcement will be soon and we will all enjoy a nice ride up. If they have anything of real substance the market cap could easily jump to the $100-150 million range. That's why I'm here. A nice 20-40 bagger just in time for summer.
Key management is in place.
KING-little dip .019 X .02 2 X 1
Buys coming at .02
All of the directors have been involved in NAZ, AMEX, or NYSE companies.
KING-little dip .019 X .02 2 X 1
Buys coming at .02
KING printed .022
.021 X .022 1 X 1
King printed .022 .021X.022 1X1
LOL othman- Thanks RJ